ArticleBreast cancer research and treatment2026
Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePatients with triple-negative breast cancer (TNBC) are encouraged to consider clinical trials given limited treatment options, yet little is known regarding barriers to trial participation in this population. We examined whether patient-level factors, including disease knowledge, were associated with TNBC patients' participation in trials.
methodsFrom a prospective multicenter registry of patients with newly-diagnosed TNBC, we identified those with stage I-III tumors who completed at least one survey assessing TNBC knowledge, risk perceptions, treatment rationales, and participation in trials. Accuracy of tumor characteristics reported by patients was verified with medical records. Logistic regression was used to identify factors associated with self-reported trial participation.
resultsTNBC knowledge varied among patients, with many reporting their tumor characteristics incorrectly and/or underestimating their recurrence risk. Among 116 patients with trial participation responses, 55 (47%) reported participating in a trial, including 35% who underwent upfront surgery and 66% who received neoadjuvant systemic therapy. Trial participation was less likely in upfront surgery patients (odds ratio [OR]: 0.41, 95% confidence interval [CI]: 0.20-0.89, p = 0.02) and more likely in stage II versus stage I patients (OR: 2.43, 95% CI: 1.09-5.39; p = 0.03). No associations were found with TNBC knowledge.
conclusionNearly half of patients surveyed reported participating in trials. While not significantly associated with trial participation, many patients demonstrated limited knowledge about TNBC and their prognosis. More research is needed to understand trial participation barriers and improve information delivery in this population to leverage patient engagement in developing more effective TNBC treatments.
Indexed as
Identifiers
42530769What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.